A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines

Katsumata,Kenji; Musiake,Noriyuki; Shibuya,Kentaro; Nakajima,Takahiro; Watanabe,Masato; Sasaki,Motoyuki; Sugiyama,Yasuyuki

doi:10.3892/ol.2011.279

May-June 2011 Volume 2 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-June 2011 Volume 2 Issue 3

Full Size Image

Article

A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines

Authors:
- Kenji Katsumata
- Noriyuki Musiake
- Kentaro Shibuya
- Takahiro Nakajima
- Masato Watanabe
- Motoyuki Sasaki
- Yasuyuki Sugiyama
View Affiliations / Copyright

Affiliations: Department of Surgery, Mizonokuchi Hospital of Teikyo University, Kanagawa, Japan
Pages: 509-514
|
Published online on: March 21, 2011

https://doi.org/10.3892/ol.2011.279
Expand metrics +

Abstract

The anti-tumor effect of a cyclooxygenase (COX)-2 selective inhibitor or a non-specific immunostimulant (PSK) alone, as well as the anti-tumor effect of their combined administration were examined on a hepatic metastasis model of colon cancer using a colon 26 cell line (CT26) and its highly metastatic variant. Anti-tumor effects were assessed by the number of hepatic metastases. Serum MMP-9, TGF-β and IL-6 were also measured. In a preliminary experiment, cells (5x105) of a mouse colon cancer 26 cell line (CT26) and its highly metastatic variant were implanted below the splenic capsule in BALB/c and CDF1 mice. The number of hepatic metastatic CT26 cell lesions in the CDF1 mice of the non-spleen-removed group at 2 weeks was found to be optimum for the experiments. Although no significant difference was found, etodolac treatment showed the highest inhibitory effect on the number of hepatic metastases at a concentration of 30 mg/kg. In contrast, intraperitoneal administration of 50 mg/kg PSK showed an inhibitory effect on hepatic metastases, but a significant difference was not observed. PSK (p=0.002) or the combined use of etodolac and PSK (p=0.001) exhibited a significant inhibition of the number of hepatic metastases. In addition, MMP-9 was significantly inhibited by the single use of etodolac or PSK, and was inhibited with an additive effect by the combined use of etodolac and PSK. IL-6 and TGF-β were significantly inhibited following the combined use of etodolac and PSK. In conclusion, etodolac did not exhibit any significant hepatic metastasis inhibitory effect, whereas it significantly reduced the MMP-9 level. PSK reduced both the number of hepatic metastases and MMP-9. Combined use of etodolac and PSK did not show any additive effect in the inhibition of the number of hepatic metastases, whereas it inhibited MMP-9, TGF-β and IL-6, suggesting the benefit of a combined effect.

View Figures

View References

1	Yoshimatsu K, Golijanin D, Paty PB, et al: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res. 7:3971–3976. 2001.PubMed/NCBI
2	Takeda H, Sonoshita M, Oshima H, et al: Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 63:4872–4877. 2003.PubMed/NCBI
3	Seno H, Oshima M, Ishikawa T, et al: Cyclooxygenase-2 and prostaglandin E₂ receptor EP₂-dependent angiogenesis in Apc^Δ716 mouse intestinal polyps. Cancer Res. 62:506–511. 2002.PubMed/NCBI
4	Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997. View Article : Google Scholar : PubMed/NCBI
5	Tomozawa S, Nagawa H, Tsuno N, et al: Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer. 81:1274–1279. 1999. View Article : Google Scholar : PubMed/NCBI
6	Kune GA, Kune S and Watson LF: Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48:4399–4404. 1988.PubMed/NCBI
7	Matsunaga N, Yamada N and Hirakawa K: Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitor for liver metastasis of colon cancer. Nippon Rinsho. 61:487–489. 2003.(In Japanese).
8	Zhang H, Morisaki T, Matsunaga H, et al: Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-β1 and MMPs. Clin Exp Metastasis. 18:343–352. 2000.PubMed/NCBI
9	Irie T, Tsujii M and Tsuji S: The effect of COX on tumor progression. Ganchiryou to Shukushu Frontiers in Cancer Treatment. 16:17–21. 2004.
10	Peluffo GD, Stillitani I, Rodriguez VA, et al: Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal anti-inflammatory drugs. Int J Cancer. 110:825–830. 2004. View Article : Google Scholar : PubMed/NCBI
11	Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352:1092–1102. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kerr DJ, Dunn JA, Langman MJ, et al: Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 357:360–369. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ogata J, Sakamoto N, Hisada M, Wada T, Kato K, Aoki T and Koyanagi Y: Experimental study on the antitumor effect of a selective cyclooxygenase-2 inhibitor combined with 5-fluorouracil in a mouse model of colon cancer. J Tokyo Med Univ. 61:336–345. 2003.
14	Ishizaki T, Katsumata K, Tsuchida A, et al: Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med. 17:357–362. 2006.PubMed/NCBI
15	Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 343:1122–1126. 1994. View Article : Google Scholar : PubMed/NCBI
16	Toge T and Yamaguchi Y: Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncology. 7:1157–1161. 2000.
17	Ohwada S, Ikeya T, Yokomori T, et al: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomized controlled study. Br J Cancer. 90:1003–1010. 2004. View Article : Google Scholar : PubMed/NCBI
18	Yoshitani S and Takashima S: Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. Cancer Biother Radiopharm. 24:35–39. 2009. View Article : Google Scholar : PubMed/NCBI
19	Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H and Ohashi Y: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 55:404–411. 2006. View Article : Google Scholar
20	Yoshino S, Hazama S, Shimizu R, et al: Immunoregulatory effects of PSK on the balance between Th1 and Th2 in patients with colorectal cancer. Biotherapy. 17:26–31. 2003.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles